To summarize if there were seen 1 week prior to their first ACS events, 51% of them were not recommended for statin therapy based on their ASCVD risk score and 67% of patients either had no chest pain until the event or chest pain within 48hrs of onset of their ACS and consequently ...
To summarize if there were seen 1 week prior to their first ACS events, 51% of them were not recommended for statin therapy based on their ASCVD risk score and 67% of patients either had no chest pain until the event or chest pain within 48hrs of onset of their ACS and consequently ...
Overall, CAC screening reclassified ASCVD risk in 2,026 patients, or roughly one in five individuals. When compared with individuals with zero calcification, those with a CAC score > 400 were significantly more likely to be prescribed a statin, including high-intensity therapy, and aspirin. ...
ASCVD Acronyms Arteriosclerotic cardiovascular disease. SeeAtherosclerosis, Artherosclerotic heart disease. McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc. Want to thank TFD for its existence?Tell a friend about us, add a link to this page, or visit...
891 individuals were calculated for the 10-year ASCVD risk.Then the distribution of 4 statin benefit groups and the situation of an estimated 10-year ASCVD risk of 7.5% or higher were respectively found.Results Seven hundred and fifty-one patients were benefited from four statin treatments in ...
statin in China, India, and Thailand[J].J Clin Lipidol. 2020,14(1):98-108. [4] Yi Li, et al.Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk:The OPT...
1. J.R. Gonzalez Juanate. Are patients paying the price for our inertia? 2041. ESC 2019. 2. Robinson JG, Watson KE. Identifying Patients for Nonstatin Therapy. Rev Cardiovasc Med. 2018;19(S1):S1-S8. 3. Federico Vancheri, Lars Backlund, Lars-Erik Strender, et al.Time trends in sta...
Michos: Women tend to be very under-enrolled in cardiovascular clinical trials, relative to the disease burden in the population, but in this trial, there's about half enrollment of women, which is important. Likely because of the eligibility of statin intolerance, as this affects women more....
[70].YeohA,CheungR,AhmedA,ChitnisAS,DoA,WongRJ.CardiovascularDiseaseRiskandStatinUseAmongAdultswithMetabolicDysfunctionAssociatedFattyLiverDisease.AmJMed.Mar302023;doi:10.1016/j.amjmed.2023.03.010[71].AyadaI,vanKleefLA,ZhangH,etal.Dissectingthemultifacetedimpactofstatinuseonfattyliverdisease:amultidimensional...
first-line treatment to prevent recurrent ASCVD events in secondary prevention patients, ezetimibe and PCSK9 inhibitors are evidence-based non-statin agents that can be used when residual on top of maximally tolerated statin therapy in patients deemed to be at very-high risk of recurrent ASCVD ...